The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
Official Title: A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters on Advanced Pancreatic Cancer
Study ID: NCT04002479
Brief Summary: A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer.
Detailed Description: This is a prospective, single-center, open label, single arm study. The study is designed to evaluate the feasibility, safety and preliminary efficacy of intratumoral alpha radiation mediated treatment with Alpha DaRT seeds for the treatment of advanced pancreatic cancer. The study will be comprised of a screening period, DaRT insertion visit, acute follow-up phase of 4-6 weeks and a long-term follow up phase of 24 months. The total duration of the study will be 24 months from the DaRT insertion procedure. 30 patients with advanced pancreatic cancer will be recruited by the investigational site. Eligible patients who meet inclusion/exclusion criteria (as assessed during the screening period) will be invited to the site for the procedure of DaRT seeds insertion. The patients will be monitored for a period of 24 months post insertion.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada
Jewish General Hospital, Montréal, Quebec, Canada
Name: David Donath, MD
Affiliation: Brachytherapy Service Centre Hospitalier de l'Université de Montreal
Role: PRINCIPAL_INVESTIGATOR
Name: Corey Miller, MD
Affiliation: Division of Gastroenterology, Jewish General Hospital
Role: PRINCIPAL_INVESTIGATOR